A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)

StatusActive, Not Recruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 2 years later Oct 1, 2026 → Oct 1, 2028
See other at-risk trials from M.D. Anderson Cancer Center

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Oct 1, 2026 to Oct 1, 2028
    • Study description expanded, about 9 words
    • Eligibility criteria expanded, about 4 words
  2. Re-verified, no change to tracked fieldsv13
  3. Study sites: 1 to 2v12
  4. 3 versions Re-verified since May 30, 2025, no change to tracked fieldsv9-v11
  5. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 29 to confirmed 10
    • Site details revised
    v8
Show 6 earlier versionsHide 6 earlier versions
  1. Primary completion date: Oct 1, 2024 to Oct 1, 2026v7
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Sep 30, 2024 to Aug 7, 2024
    • Site details revised
    v6
  3. Enrollment target: 10 to 29v5
  4. 2 versions Re-verified since Jun 26, 2024, no change to tracked fieldsv3-v4
  5. Start date: Jul 31, 2024 to Sep 30, 2024v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To learn if evolocumab and nivolumab can control metastatic and refractory renal cell carcinoma. The safety of this drug combination will also be studied.
Trial Details
NCT Number NCT06284564
Lead Sponsor M.D. Anderson Cancer Center
Collaborators: Bristol-Myers Squibb, Cancer Prevention Research Institute of Texas, United States Department of Defense
Conditions
(from sponsor)		 Metastatic Renal Cell Carcinoma
Related terms Carcinoma, Renal Cell
Enrollment 10 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov